Our Board

The Board adds critical and broad experience to Transine® and fully supports its ambition to realise the promise of the ground-breaking SINEUP® technology.

Christian Jung, PhD

Chairman

Christian joined the DDF as Partner in 2019 and led the investment in Transine. Christian joined the DDF from Wellington Partners and before that was a Senior Investment Manager with High-Tech Gründerfonds where he completed and led the investments in nine seed- and early-stage companies, including Amal Therapeutics (acquired by Boehringer Ingelheim in 2019), Rigontec (acquired by MSD in 2017) and Cunesoft (acquired by Phlexglobal in 2019).

Jan Thirkettle, PhD

CEO

Jan has more than 20 years’ experience of building cross functional teams to drive delivery of innovative technologies. He has built platforms and played a leadership role in the commercialisation of therapeutics across small molecule, biopharmaceutical and gene therapy modalities. Jan joined Transine Therapeutics from Freeline Therapeutics where he was start-up CEO then Chief Development Officer overseeing deployment of a novel AAV platform and a rapidly growing clinical-phase portfolio. Prior to this Jan spent close to 20 years at GSK in multiple senior roles spanning from Discovery to Manufacturing environments, latterly oversing the establishment of the Cell & Gene Therapy platform unit where he played a pivotal role in the commercialisation of Strimvelis, the first ex-vivo gene therapy to receive an EU Marketing Authorisation Application. He has served on multiple advisory boards in the CMC and regulatory space, playing a significant role in the shaping of the Cell and Gene therapy field. Jan holds an MA in Chemistry and a DPhil. in Biological Chemistry from Oxford University.

Miles Gerson

Director

Miles joined Takeda Ventures, Inc. (TVI) in April 2020, as a Sr. Partner, and is based in Cambridge, Massachusetts. He currently serves as Board Director or Observer at the Board of four TVI portfolio companies, including Catamaran Bio, Inc., ImmPACT, Bio, Inc., and Carmine Therapeutics, Ltd. Prior to joining TVI, Miles held multiple operational roles spanning founding management, head of finance, head of business development, and head of legal for venture-backed & publicly-traded companies, as well as serving as UCLA’s Managing Officer of Business Development.

Michael Jones, PhD

Founder Director

With significant experience in both industrial and academic research, Mike has published extensively on genomic analysis and cancer research. Combining his research skills with his significant experience in business development, in 2010 Mike founded and became CEO of Cell Guidance Systems which has developed a plug-and-play protein therapeutic platform that offers potential for many intractable diseases.

Professor Alan Boyd, PhD

Independent Director

A clinician by training, Alan is a highly experienced individual who has led the development of a gene-based medicine portfolio and has significant experience in large pharma, biotech and academia. Alan brings significant expertise in viral delivery for projects across a range of therapeutic areas. His expertise in medicines development has been recognised with an Honorary Professorship at the University of Birmingham and in 2014 he was elected Fellow of the Royal Society of Biology.

Mary Canning

Principal, Epidarex

Mary Canning is a Principal with Epidarex Capital, a transatlantic venture fund focused on building highly innovative early-stage life science companies in the UK and US. Mary leads due diligence for Epidarex investments and holds board positions with portfolio companies LUNAC Therapeutics and Caldan Therapeutics. She also serves as an independent director with GU Holdings Ltd, the University of Glasgow's investment company for spin-out activity. Prior to joining Epidarex, she led commercialisation of IP from several MRC research institutes. She has a PhD from the University of Edinburgh.

Get in Touch

For more information about Transine, you can email the team via info@transinetx.com or contact us below.

Contact us